

BIO-PHARMA INVESTS IN TORONTO REGION

Pharmaceutical companies have invested more than \$1.1 billion in local R&D in the region over the past decade, including:

- Aventis Pasteur's (now Sanofi Pasteur) \$350 million investment over 10 years for a worldwide Cancer Vaccine Program, anchored at a \$25 million corporate research campus and at the Sunnybrook and Women's College Health Sciences Centre.
- AstraZeneca's \$250 million investment over 10 years for facility expansion and the creation of 700 new jobs.
- The Structural Genomics Consortium at the University of Toronto – funded by a landmark \$70 million grant from the Wellcome Trust in the UK and support from GlaxoSmithKline – for research on over 350 proteins that will be made available to scientists worldwide.
- Eli Lilly's 65,000 square foot research facility at Sunnybrook and Women's College Health Sciences Centre, which has global mandates to improve the effectiveness of drugs under development for osteoporosis, health disease, cancer, mental health and infectious diseases.
- Apotex's new \$150 million R&D facility, which be the largest of its kind in Canada.